CA
NZ
UK
AU
IND
US
…
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
T2 Biosystems develops rapid infectious-disease diagnostics using a proprietary T2 magnetic resonance platform that detects pathogens directly from whole blood without culture. Long-term growth drivers include wider hospital adoption of rapid sepsis testing, new product approvals, and recurring consumable sales that could support revenue. The company may benefit from healthcare demand for faster diagnostics and potential cost-savings in inpatient care.
Key risks include limited commercial traction, ongoing losses and potential financing needs, regulatory and reimbursement hurdles, and competition from established diagnostics companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -62.32M | -49.24M | -46.80M | -59.01M | -51.15M |
| Net income | -63.37M | -53.49M | -49.21M | -63.11M | -51.15M |
| Selling general administrative | 30.62M | 28.53M | 21.29M | 27.30M | 25.70M |
| Gross profit | 1.17M | 7.36M | -3.15M | -8.43M | -4.90M |
| Reconciled depreciation | 2.27M | 2.54M | 3.16M | 3.64M | 2.45M |
| Ebit | -55.51M | -42.97M | -41.36M | -52.06M | -46.92M |
| Ebitda | -55.47M | -42.66M | -41.29M | -51.66M | -44.47M |
| Depreciation and amortization | 0.04M | 0.32M | 0.06M | 0.40M | 2.45M |
| Non operating income net other | - | - | 0.09M | 0.40M | 0.62M |
| Operating income | -55.51M | -42.97M | -41.36M | -52.06M | -45.09M |
| Other operating expenses | 77.81M | 71.03M | 59.49M | 60.39M | 55.59M |
| Interest expense | 6.08M | 6.59M | 5.50M | 7.35M | 6.68M |
| Interest income | 0.01M | 0.11M | 0.01M | 7.35M | 6.68M |
| Net interest income | -6.08M | -6.47M | -5.50M | -7.35M | -6.68M |
| Income tax expense | 1.05M | 4.25M | 2.41M | 4.11M | 0.62M |
| Total revenue | 22.30M | 28.06M | 18.13M | 8.34M | 10.50M |
| Total operating expenses | 56.68M | 50.33M | 38.21M | 43.63M | 40.19M |
| Cost of revenue | 21.14M | 20.70M | 21.28M | 16.76M | 15.40M |
| Total other income expense net | -6.81M | -6.27M | -5.44M | -6.95M | 0.62M |
| Net income from continuing ops | -62.00M | -49.24M | -46.80M | -59.01M | -51.15M |
| Net income applicable to common shares | -62.65M | -49.24M | -46.80M | -59.01M | -51.15M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 34.80M | 34.39M | 60.54M | 79.08M | 28.49M |
| Other current assets | 3.16M | 2.58M | 3.11M | 2.66M | 1.44M |
| Total liab | 62.83M | 74.36M | 73.44M | 70.35M | 62.49M |
| Total stockholder equity | -28.04M | -39.97M | -12.90M | 8.73M | -34.01M |
| Deferred long term liab | - | - | - | 0.10M | - |
| Other current liab | 11.50M | 7.69M | 7.16M | 6.36M | 13.63M |
| Common stock | 0.00M | 0.01M | 0.17M | 0.15M | 0.05M |
| Capital stock | 0.00M | 0.01M | 0.17M | 0.15M | 0.05M |
| Retained earnings | -584.30M | -534.53M | -472.22M | -422.98M | -376.18M |
| Other liab | - | 4.90M | 4.61M | 4.78M | 0.05M |
| Other assets | 0.00M | 1.69M | 1.70M | 0.69M | 0.39M |
| Cash | 15.69M | 10.33M | 22.25M | 16.79M | 11.03M |
| Total current liabilities | 56.15M | 10.51M | 11.69M | 9.80M | 60.57M |
| Current deferred revenue | 0.22M | 0.17M | 0.52M | 0.23M | 0.28M |
| Net debt | 33.81M | 48.89M | 34.90M | 38.98M | 33.74M |
| Short term debt | 42.90M | 1.35M | 1.17M | 1.15M | 42.90M |
| Short long term debt | 41.28M | - | - | - | 42.90M |
| Short long term debt total | 49.50M | 59.22M | 57.15M | 55.77M | 44.77M |
| Other stockholder equity | 556.26M | 494.56M | 459.15M | 431.55M | 342.12M |
| Property plant equipment | - | 13.27M | 14.44M | 14.80M | 5.84M |
| Total current assets | 25.09M | 19.42M | 44.39M | 53.58M | 18.89M |
| Long term investments | - | - | 0.00M | 10.00M | - |
| Net tangible assets | - | -39.97M | -12.90M | 8.73M | -32.09M |
| Short term investments | - | 0.00M | 10.00M | 25.40M | - |
| Net receivables | 1.42M | 2.16M | 5.13M | 5.10M | 2.83M |
| Long term debt | - | 49.65M | 47.79M | 45.23M | - |
| Inventory | 4.82M | 4.35M | 3.91M | 3.64M | 3.60M |
| Accounts payable | 1.53M | 1.30M | 2.83M | 2.06M | 3.75M |
| Accumulated other comprehensive income | 0.00M | - | -0.00M | 0.01M | -13.24M |
| Common stock total equity | - | - | - | 0.15M | 0.05M |
| Retained earnings total equity | - | - | - | -422.98M | -376.18M |
| Non currrent assets other | 0.00M | 1.69M | 1.70M | 0.69M | 0.39M |
| Non current assets total | 9.71M | 14.97M | 16.14M | 25.49M | 9.59M |
| Capital lease obligations | 8.21M | 9.57M | 9.36M | 10.53M | 3.86M |
| Long term debt total | - | - | - | 45.23M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 9.66M | 25.25M | -35.46M | -0.76M | -0.59M |
| Change to liabilities | 0.00M | 0.65M | -1.33M | 6.67M | -0.16M |
| Total cashflows from investing activities | - | 24.79M | -36.26M | -0.76M | -0.59M |
| Net borrowings | - | - | - | -0.88M | -1.55M |
| Total cash from financing activities | 29.05M | 20.54M | 85.61M | 6.35M | 49.66M |
| Change to operating activities | - | -0.85M | -3.38M | 1.35M | -0.85M |
| Net income | -62.00M | -49.24M | -46.80M | -59.01M | -51.15M |
| Change in cash | -11.92M | 6.45M | 6.13M | -39.77M | 8.93M |
| Begin period cash flow | 23.80M | 17.34M | 11.21M | 50.98M | 42.06M |
| End period cash flow | 11.88M | 23.80M | 17.34M | 11.21M | 50.98M |
| Total cash from operating activities | -50.63M | -38.87M | -43.22M | -45.36M | -40.14M |
| Issuance of capital stock | 29.46M | 19.97M | 85.31M | 6.65M | 51.20M |
| Depreciation | 2.27M | 2.54M | 3.16M | 3.64M | 2.45M |
| Other cashflows from investing activities | - | - | 0.00M | - | - |
| Change to inventory | -0.95M | -1.94M | 0.44M | -0.91M | -1.09M |
| Change to account receivables | 2.97M | -0.04M | -2.27M | -1.04M | -1.32M |
| Sale purchase of stock | -0.33M | - | - | 0.58M | 1.97M |
| Other cashflows from financing activities | 0.22M | 0.57M | 0.30M | 0.58M | -0.59M |
| Change to netincome | - | 10.00M | 6.96M | 8.14M | 12.51M |
| Capital expenditures | 0.34M | 0.46M | 0.80M | 0.76M | 0.59M |
| Change receivables | - | - | -2.27M | -1.04M | -1.32M |
| Cash flows other operating | - | - | -1.52M | -1.41M | -1.38M |
| Cash and cash equivalents changes | - | - | 6.13M | -39.77M | 8.93M |
| Change in working capital | -0.50M | -2.17M | -6.54M | 1.86M | -3.94M |
| Stock based compensation | 6.49M | 7.09M | 3.91M | 5.46M | 9.90M |
| Other non cash items | 3.11M | 3.93M | 3.31M | 2.41M | 2.00M |
| Free cash flow | -50.97M | -39.33M | -44.02M | -46.12M | -40.73M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TTOO T2 Biosystems Inc |
-0.00 10.00% |
0.01 | 0.04 | - | 2.41 | 14.50 | 7.13 | -1.17 |
| TMO Thermo Fisher Scientific Inc |
-15.12 2.11% |
702.59 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-1.34 0.57% |
233.97 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
24.91 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.17 0.68% |
24.93 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
101 Hartwell Avenue, Lexington, MA, United States, 02421
781 761 4646
113
| Name | Title | Year Born |
|---|---|---|
| Mr. John J. Sperzel III, B.Sc. | Pres, CEO & Chairman | 1963 |
| Mr. Michael Terrence Gibbs Esq. | Sr. VP & Gen. Counsel | 1971 |
| Mr. Alec J. Barclay | Sr. VP | 1980 |
| Mr. John M. Sprague CPA | Chief Financial Officer | 1958 |
| Ms. Kelley J. Morgan | Chief People Officer | 1976 |
| Dr. Aparna Jha Ahuja M.D. | Chief Medical Officer & Chairman of Scientific Advisory Board | 1967 |
| Mr. Brett A. Giffin | Chief Commercial Officer | 1959 |
| Dr. Roger Smith Ph.D. | Sr. VP of Science R&D | 1965 |
| Mr. John J. Sperzel III, B.Sc. | President, CEO & Chairman | 1963 |
| Mr. Michael Terrence Gibbs Esq. | Senior VP, General Counsel & Company Secretary | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...